AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography (DECT) with oblique sagittal reconstructions
Number of subjects: 27
Study 24337491 — intervention group
Group type: COMPARATOR
Intervention: Other techniques (not specified)
Number of subjects: 27
Study 22206075 — intervention group
Group type: EXPERIMENTAL
Intervention: RT001 Botulinum Toxin Type A Topical Gel
Number of subjects: 90
Study 22206075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20183681 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions focusing on stress and coping
Number of subjects: 0
Study 20183681 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 17565914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine administered pre‐incisionally and intraperitoneally (Group 1, n=14)
Number of subjects: 45
Study 17565914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine administered pre‐incisionally and intraperitoneally (Group 2, n=17)
Number of subjects: 45
Study 17565914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine administered intraperitoneally and locally at incision sites (Group 3, n=14)
Number of subjects: 45
Study 17565914 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study 15019739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry-containing mouthwash (NDM)
Number of subjects: 59
Study 15019739 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 59
Study 11450599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with cat epithelial extract
Number of subjects: 40
Study 11450599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9486679 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 108
Study 9486679 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 108
Study 7850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2
Number of subjects: 10
Study 7850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 90 mg/m2
Number of subjects: 10
Study 7850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 120 mg/m2
Number of subjects: 10
Study 7850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete hepatic venous isolation and extracorporeal chemofiltration
Number of subjects: 10
Study 7850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic and systemic MTD of doxorubicin
Number of subjects: 10
Study 3049403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous, followed by oral, metoprolol
Number of subjects: 129
Study 3049403 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 129
Study 31181631 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT5 FFQ
Number of subjects: 100
Study 27807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment in patients on prior antiplatelet treatment
Number of subjects: 500
Study 27807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment in patients not on prior antiplatelet treatment
Number of subjects: 500
Study 27807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion in patients on prior antiplatelet treatment
Number of subjects: 500
Study 27807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion in patients not on prior antiplatelet treatment
Number of subjects: 500
Study 27807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage in patients on antiplatelet treatment
Number of subjects: 500
Study 27807281 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic intracranial hemorrhage in patients without antiplatelet treatment
Number of subjects: 500
Study 26194461 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus NP-delivered symptom management intervention (proactive telephone calls during the week after each of the first 2 chemotherapy visits)
Number of subjects: 120
Study 26194461 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 120
Study 23564803 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 537
Study 22484874 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (34% Tooth Conditioner Gel + Adper Single Bond 2 + Z100)
Number of subjects: 30
Study 22484874 — intervention group
Group type: COMPARATOR
Intervention: Bonded amalgam (34% Tooth Conditioner Gel + Prime and Bond 2.1 + Permite C)
Number of subjects: 30
Study 19486950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mytomicin-c chemotherapy after surgical resection
Number of subjects: 0
Study 17112851 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids at usual doses (Group A)
Number of subjects: 150
Study 17112851 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids at 50% lower doses (Group B)
Number of subjects: 150
Study 15206528 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 15206528 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninferiority trial
Number of subjects: 0
Study 15206528 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninferiority test procedure
Number of subjects: 0
Study 12622457 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata Extract (BSE)
Number of subjects: 30
Study 12622457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10859288 — intervention group
Group type: COMPARATOR
Intervention: 325 mg ASA daily
Number of subjects: 18
Study 10859288 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg ASA + 75 mg clopidogrel daily
Number of subjects: 18
Study 10859288 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg ASA daily + 300 mg clopidogrel loading dose on day 1 and +75 mg clopidogrel per day on days 2 to 10
Number of subjects: 18
Study 9191583 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine during 64 hours of sleep deprivation
Number of subjects: 0
Study 1528095 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% prilocaine hydrochloride spray
Number of subjects: 40
Study 1528095 — intervention group
Group type: COMPARATOR
Intervention: 1.1% dipucaine ointment
Number of subjects: 40
Study 3698654 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release diazepam (10 mg)
Number of subjects: 231
Study 3698654 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release diazepam (15 mg)
Number of subjects: 231
Study 3698654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 30247074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 500 mg every 6 hours for the first three days of menstruation
Number of subjects: 100
Study 30247074 — intervention group
Group type: COMPARATOR
Intervention: Oral micronised flavonoids 500 mg every 6 hours for the first three days of menstruation
Number of subjects: 100
Study 27146615 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 µg/kg) and propofol
Number of subjects: 146
Study 27146615 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (20 mg/kg) and propofol
Number of subjects: 146
Study 23832323 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid activation in rotator cuff tear patients preoperatively
Number of subjects: 55
Study 23832323 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid activation in rotator cuff tear patients postoperatively
Number of subjects: 55
Study 23832323 — intervention group
Group type: COMPARATOR
Intervention: Deltoid activation in controls with large abduction moment loading
Number of subjects: 55
Study 22758930 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) and elements of the Bobath concept
Number of subjects: 84
Study 22758930 — intervention group
Group type: COMPARATOR
Intervention: Traditional kinesiotherapy
Number of subjects: 84
Study 19967335 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional locking plates
Number of subjects: 40
Study 19967335 — intervention group
Group type: COMPARATOR
Intervention: Multidirectional locking plates
Number of subjects: 40
Study 18237578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary factors including fiber, phytostanols/phytosterols, n‐3 fatty acids, Mediterranean diet, and other plant‐based approaches
Number of subjects: 0
Study 18237578 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids, trans‐fatty acids, and cholesterol
Number of subjects: 0
Study 15616863 — intervention group
Group type: EXPERIMENTAL
Intervention: Metric tone sequences (higher-order, periodic structure)
Number of subjects: 0
Study 15616863 — intervention group
Group type: COMPARATOR
Intervention: Heavy beat tone sequences
Number of subjects: 0
Study 15616863 — intervention group
Group type: COMPARATOR
Intervention: Irregular tone sequences
Number of subjects: 0
Study 15616863 — intervention group
Group type: COMPARATOR
Intervention: Light beat tone sequences (absent accents)
Number of subjects: 0
Study 12772581 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chitosan mouthrinse for 14 days, rinsing with 20 ml twice daily for 30 seconds
Number of subjects: 24
Study 12772581 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 24
Study 10713862 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg every 8 h)
Number of subjects: 144
Study 10713862 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1,000 mg every 12 h)
Number of subjects: 144
Study 7499650 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent mepivacaine
Number of subjects: 60
Study 7499650 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent prilocaine
Number of subjects: 60
Study 7499650 — intervention group
Group type: COMPARATOR
Intervention: 2 percent lidocaine plus 1:100,000 epinephrine
Number of subjects: 60
Study 2021719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl
Number of subjects: 85
Study 2021719 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 85
Study 6123760 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cuff (12 X 23 cm)
Number of subjects: 1240
Study 6123760 — intervention group
Group type: COMPARATOR
Intervention: Three standard adult cuff sizes
Number of subjects: 1240
Study 6123760 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulae and a table for correction
Number of subjects: 1240
Study 6123760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence estimation
Number of subjects: 1240
Study 31981279 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateletcrit (PCT)
Number of subjects: 567
Study 31054140 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing and transcriptomic analysis of sclerotial development
Number of subjects: 0
Study 31054140 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real‐time reverse transcription PCR validation of gene expression profiles
Number of subjects: 0
Study 29122067 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 32
Study 29122067 — intervention group
Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 32
Study 26086066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d) for 20 days
Number of subjects: 75
Study 26086066 — intervention group
Group type: COMPARATOR
Intervention: Water (control group) for 20 days
Number of subjects: 75
Study 23841265 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine treatment group (Group B) - FGG
Number of subjects: 200
Study 23841265 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A) - Voltaren Tablet
Number of subjects: 200
Study 23841265 — intervention group
Group type: COMPARATOR
Intervention: Ozone group (Group C) - Ozone injection (10-18 mL, 25 mg/L, once weekly for 4 weeks)
Number of subjects: 200
Study 23841265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine treatment plus ozone group (Group D) - FGG and ozone injection
Number of subjects: 200
Study 20653988 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated mortality risk score
Number of subjects: 69
Study 19339779 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of galantamine and memantine
Number of subjects: 2113
Study 19339779 — intervention group
Group type: COMPARATOR
Intervention: Galantamine alone
Number of subjects: 2113
Study 16696459 — intervention group
Group type: EXPERIMENTAL
Intervention: OS-based features from tumor regions
Number of subjects: 84
Study 16696459 — intervention group
Group type: COMPARATOR
Intervention: OS-based features from normal tissue regions
Number of subjects: 84
Study 15297790 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment (16-32 mg/kg/day) for 6 days
Number of subjects: 33
Study 15297790 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 12199273 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA replacement therapy
Number of subjects: 0
Study 12199273 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study 9699744 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate intake (450 or 850 microg/day) provided as food folate (120 microg/day) and supplemental folic acid (330 or 730 microg/day) for 12 weeks
Number of subjects: 2
Study 9699744 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonpregnant women)
Number of subjects: 2
Study 7911921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (NIPPV) for at least 6 hours nocturnally (n = 35)
Number of subjects: 70
Study 7911921 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 35)
Number of subjects: 70
Study 7911921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (NIPPV)
Number of subjects: 70
Study 2589383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) alone
Number of subjects: 10
Study 2589383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Clindamycin (600 mg)
Number of subjects: 10
Study 2589383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) + Metronidazole (500 mg)
Number of subjects: 10
Study 1089875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid, 750 mg per day
Number of subjects: 36
Study 1089875 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital, 180 mg per day
Number of subjects: 36
Study 1089875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chenodeoxycholic acid and phenobarbital
Number of subjects: 36
Study 1089875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7399948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 0
Study 7399948 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg postoperative (n=107)
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 0.6 mg/kg postoperative (n=65)
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 1.2 mg/kg postoperative (n=108)
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg postoperative (n=106)
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg preoperative (n=109)
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg preoperative (n=108)
Number of subjects: 813
Study 31935028 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily (n=105)
Number of subjects: 813
Study 31935028 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 2.5 mg twice daily (n=105)
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 0.6 mg/kg postoperative
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 1.2 mg/kg postoperative
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg postoperative
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 1.8 mg/kg preoperative
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg postoperative
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab 0.3 mg/kg preoperative
Number of subjects: 813
Study 31935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Osocimab
Number of subjects: 813
Study 31935028 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 813
Study 31935028 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 813
Study 31208927 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy during recovery (intervention group)
Number of subjects: 56
Study 31208927 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study 29407718 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (CBIT, Comprehensive Behavioral Intervention for Tics)
Number of subjects: 0
Study 29407718 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation plus supportive therapy (PST)
Number of subjects: 0
Study 27008620 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS to the left DLPFC
Number of subjects: 60
Study 27008620 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 25451890 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50mg three times a day)
Number of subjects: 41
Study 25451890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50mg once a day)
Number of subjects: 41
Study 25451890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of miglitol and sitagliptin (M+S)
Number of subjects: 41
Study 22061864 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infusion
Number of subjects: 265
Study 22061864 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (RIS) 5 mg oral daily
Number of subjects: 265
Study 19758359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 390
Study 19758359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 390
Study 19758359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 18173915 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training group (n = 35) performing 3 sessions per week of aquatic training (32 degrees C) for 16 weeks
Number of subjects: 60
Study 18173915 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) of healthy women matched for age, weight, body mass index, and educational and physical activity levels
Number of subjects: 60
Study 12921554 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 100
Study 12921554 — intervention group
Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 100
Study 10866439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Number of subjects: 726
Study 10866439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg
Number of subjects: 726
Study 10866439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 10866439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg (in patients treated within 24 h of symptom onset)
Number of subjects: 726
Study 10866439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg (in patients treated within 24 h of symptom onset)
Number of subjects: 726
Study 10866439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients treated within 24 h of symptom onset)
Number of subjects: 726
Study 10866439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 726
Study 9383256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for 4 weeks during pollen season
Number of subjects: 20
Study 1586708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose methylprednisolone (LDM)
Number of subjects: 68
Study 1586708 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose methylprednisolone (HDM)
Number of subjects: 68
Study 3709398 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 2
Study 3709398 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 2
Study 31096275 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 711
Study 31096275 — intervention group
Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 711
Study 28317149 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride arm
Number of subjects: 1157
Study 26152562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg, then 90 mg BID for 7-9 days)
Number of subjects: 34
Study 26152562 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg, then 75 mg QD for 7-9 days)
Number of subjects: 34
Study 24105694 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNa2a at 90 μg/week
Number of subjects: 221
Study 24105694 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNa2a at 45 μg/week
Number of subjects: 221
Study 24105694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 90 μg/week
Number of subjects: 221
Study 24105694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 45 μg/week
Number of subjects: 221
Study 24105694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 90 μg/week after dose amendment
Number of subjects: 221
Study 24105694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 45 μg/week after dose amendment
Number of subjects: 221
Study 21986118 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative insertion of an intra-aortic balloon pump (IABP)
Number of subjects: 232